<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220843</url>
  </required_header>
  <id_info>
    <org_study_id>PI10-PR-CHOUKROUN-1</org_study_id>
    <secondary_id>2010-020872-49</secondary_id>
    <nct_id>NCT01220843</nct_id>
  </id_info>
  <brief_title>FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease</brief_title>
  <acronym>FRENCH</acronym>
  <official_title>Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate in Chronic Kidney Disease (CKD) patients not on
      dialysis and who have an Fibroblast growth factor 23 (FGF23) serum levels elevated, the
      effect of non calcic phosphate binder: sevelamer carbonate. This treatment could lead to a
      diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary
      phosphate. In addition, the investigators will describe the impact of the FGF23 level
      monitoring on the main phosphocalcium metabolism markers as phosphatemia, intact parathyroid
      hormone (iPTH), serum calcitriol and phosphaturia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total length of the study is 14 weeks divided in 2 parts the first part is the screening
      period she will stay 1 to 2 weeks and the second period with the treatment with permanent
      dosage during 12 weeks.

      During the screening visit (Vo) inclusion and non inclusion criteria will be checked and the
      patient consent will be collected. Biological analysis will be performed.

      If the patient still eligible after the reception of biological results, he will be
      randomized and will received, either sevelamer carbonate, either placebo. The study treatment
      will be begun at the randomisation visit (V1) the dosage will be 2 tablets 3 times per day
      (corresponding to 4.8g/d sevelamer carbonate for patient taken active medication).

      Patient will be seen every 2 weeks after the first visit (+/-5days) during 6 weeks
      (visit2/day15, visit3/day30, visit4/day45) and 12 weeks after the randomisation visit
      (visit5/day90). This visits will include biological analysis, compliance evaluation, adverse
      events report, concomitant treatments reports.

      After the consent signature, all the adverse events will be collected until the end of the
      study for the patient (Visit5 or end of the study visit). Serious adverse events will be
      collected until 30 days after the date of the end of the study.

      The same dosage of the study treatment will be followed during all the study period except if
      the phosphatemia (evaluated during one analysis) is found above the normal range planned by
      the protocol. In this case, the dosage adaptations will be :

        -  If during a visit the phosphatemia is above or equal to 0.8 mmol/l and superior to 0.5
           mmol/l, the study treatment dosage need to be reduce to 2 tablets 3 times per day to 1
           tablet 3 times per day.

        -  If during the next blood punction, the phosphatemia still or equal to 0.8 mmol/l and
           superior to 0.5 mmol/l, the study treatment will be stopped and a &quot;end of study&quot; visit
           will be performed.

        -  If during one study visit, the phosphatemia is above or equal to 0.5 mmol/l,the study
           treatment will be stopped immediately and a end of study visit will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the serum levels of C terminal segment of fibroblast growth factor 23 (FGF23) and evaluation of sevelamer carbonate effect on this levels in comparison with placebo</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
    <description>Indeed the sevelamer carbonate could lead to a diminution of FGF23 serum levels due to the diminution of intestinal absorption of dietary phosphate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the serum levels of iPTH</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the serum levels of calcitriol (1 25(OH)2D3)</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the serum levels of others mineral metabolism parameters (phosphore, calcium, intact FGF-23 , 25(OH)D3, bone specific alkaline phosphatases, osteocalcin, collagen crosslink, C reactive protein)</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the urinary levels of phosphate</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the urinary levels of calcium</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the urinary levels of creatinine</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the urinary levels of urea</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of sevelamer carbonate effect on the serum and urinary levels of specific biomarkers (serum : fetuin A, para-cresyl sulfate, osteopontin)</measure>
    <time_frame>12 weeks after the beginning of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer carbonate</intervention_name>
    <description>dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate</description>
    <arm_group_label>Sevelamer carbonate</arm_group_label>
    <other_name>Renvela 800</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who gave their written consent

          -  Women or men over 18 years

          -  No concomitant treatment with phosphate binders

          -  CKD patients not on dialysis stage 3b or 4, as a GFR (glomerular filtration rate)
             between 15 and 45 ml/min/1.73m2, using simplified MDRD formula

          -  At the inclusion visit,patients with blood results as levels of C-terminal FGF-23 &gt;
             120 rU/ml and fasting phosphatemia &gt; 1.0 mmol/l

          -  Able to comply with the study procedures during all the study period

          -  Willing to abstain from taking any following medication during all the study period
             :antiacid and phosphate binders with aluminium, magnesium, calcium or
             lanthanum;Treatment for hyperparathyroid : active vitamin D and calcimimetic ; native
             vitamin D

          -  Female subjects who are of childbearing potential must have a reliable contraceptive
             methods during all the study period (hormonal, barrier methods or intrauterine device)

          -  No Participation in any clinical trial using an investigational product or device
             during the 30 days preceding the first protocol visit

          -  Informed patient who agreed with the utilisation of his data for the study

          -  Able to read and understand french and study objectives

          -  Inscription to medical assurance

        Exclusion Criteria:

          -  predisposition with or presence of intestinal or ileus obstruction or severe
             gastrointestinal motility disorder(like severe constipation)

          -  Antecedent of major gastrointestinal surgery

          -  Abusive consumption of alcohol and drug (exclude tabacco) according the investigator

          -  Arrythmia treated by antiarrythmic agent or epilepsia treated by anticonvulsant

          -  Antecedent of kidney transplantation

          -  Antecedent of parathyroidectomy

          -  At the inclusion visit,patients with blood results as fasting phosphatemia &gt; 1.78
             mmol/l or serum 25(OH)D3&lt; 20 ng/ml (&lt;50 nmol/)

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Choukroun, Ph D, M D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire, Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens service de nephrologie</name>
      <address>
        <city>Amiens</city>
        <zip>8000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Service de néphrologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caen service de néphrologie</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon service de néphrologie</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille Service de néphrologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier Hôpital Lapeyronie Service de Néphrologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Service de néphrologie</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon Service de Nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou Service de Nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims service de néphrologie</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Landy Centre de dialyse</name>
      <address>
        <city>Saint Ouen</city>
        <zip>93400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne Hopital Nord Service de néphrologie</name>
      <address>
        <city>St Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie - Dialyse Centre de Rein Artificiel</name>
      <address>
        <city>TASSIN la Demi Lune</city>
        <zip>69160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes hémodialyse</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy service de néphrologie</name>
      <address>
        <city>Vandeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007 Oct;22(10):2909-16. Epub 2007 May 21.</citation>
    <PMID>17517792</PMID>
  </reference>
  <reference>
    <citation>Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008 Oct;52(4):661-71. doi: 10.1053/j.ajkd.2008.06.023.</citation>
    <PMID>18805347</PMID>
  </reference>
  <reference>
    <citation>Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005 Feb;16(2):520-8. Epub 2004 Dec 22.</citation>
    <PMID>15615819</PMID>
  </reference>
  <reference>
    <citation>Vassalotti JA, Uribarri J, Chen SC, Li S, Wang C, Collins AJ, Calvo MS, Whaley-Connell AT, McCullough PA, Norris KC; Kidney Early Evaluation Program Investigators. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr;51(4 Suppl 2):S56-68. doi: 10.1053/j.ajkd.2007.12.018.</citation>
    <PMID>18359409</PMID>
  </reference>
  <reference>
    <citation>Danziger J. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant. 2008 Sep;23(9):2733-7. doi: 10.1093/ndt/gfn260. Epub 2008 May 9.</citation>
    <PMID>18469306</PMID>
  </reference>
  <reference>
    <citation>Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006 Oct;17(10):1506-13. Epub 2006 Aug 5.</citation>
    <PMID>16896512</PMID>
  </reference>
  <reference>
    <citation>Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007 Sep;18(9):2600-8. Epub 2007 Jul 26.</citation>
    <PMID>17656479</PMID>
  </reference>
  <reference>
    <citation>Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.</citation>
    <PMID>18687639</PMID>
  </reference>
  <reference>
    <citation>Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009 Sep;24(9):2792-6. doi: 10.1093/ndt/gfp191. Epub 2009 Apr 25.</citation>
    <PMID>19395730</PMID>
  </reference>
  <reference>
    <citation>Peiskerová M, Kalousová M, Kratochvílová M, Dusilová-Sulková S, Uhrová J, Bandúr S, Malbohan IM, Zima T, Tesar V. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res. 2009;32(4):276-83. doi: 10.1159/000243050. Epub 2009 Oct 1.</citation>
    <PMID>19797911</PMID>
  </reference>
  <reference>
    <citation>JP Cristol, AS Bargnoux, AM Dupuy, M Morena, A Avignon and B Canaud. Biological markers of vascular calcifications in uremia. Médecine Nucléaire 2009; 33, 53-61.</citation>
  </reference>
  <reference>
    <citation>Stubbs JR, Quarles LD. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues. 2009 May;23(6):33-4, 36-7. Review.</citation>
    <PMID>19534362</PMID>
  </reference>
  <reference>
    <citation>Westerberg PA, Linde T, Wikström B, Ljunggren O, Stridsberg M, Larsson TE. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant. 2007 Nov;22(11):3202-7. Epub 2007 Jun 13.</citation>
    <PMID>17567652</PMID>
  </reference>
  <reference>
    <citation>Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004 Aug;44(2):250-6.</citation>
    <PMID>15264182</PMID>
  </reference>
  <reference>
    <citation>Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone. 2009 Nov;45(5):949-55. doi: 10.1016/j.bone.2009.07.016. Epub 2009 Jul 23.</citation>
    <PMID>19631779</PMID>
  </reference>
  <reference>
    <citation>Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008 Jan;73(1):102-7. Epub 2007 Oct 17.</citation>
    <PMID>17943081</PMID>
  </reference>
  <reference>
    <citation>Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006 Feb;69(3):531-7.</citation>
    <PMID>16395276</PMID>
  </reference>
  <reference>
    <citation>Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010 Feb;5(2):286-91. doi: 10.2215/CJN.05420709. Epub 2009 Nov 12.</citation>
    <PMID>19965540</PMID>
  </reference>
  <reference>
    <citation>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1-130. doi: 10.1038/ki.2009.188.</citation>
    <PMID>19644521</PMID>
  </reference>
  <reference>
    <citation>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.</citation>
    <PMID>11904577</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. Erratum in: Ann Intern Med. 2008 Oct 7;149(7):519.</citation>
    <PMID>16908915</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic renal failure</keyword>
  <keyword>FGF23</keyword>
  <keyword>Sevelamer carbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

